Genentech, Inc.

University of California

Gregory Hamilton

Snahel Patel

Huifen Chen

Guiling Zhao

Craig Stivala

Blake Daniels

Wei Li

F Anthony Romero

James John Crawford

Mark Edward Zak

Simon Charles Goodacre

Paul Gibbons

F Dean Toste

Yun-Xing Cheng

Jeffrey Yung Wu

Terry Kellar

Aaron D Lackner

Robert J Phipps

Hunter Shunatona

Natalja Frueh

Yiming Wang

Jigar Patel

Takashi Honjo

Vivek Rauniyar

Some embodiments of the invention provide compounds having the general formula I: wherein R, R, Rand Rare as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.

Bicyclic ketone compounds and methods of use thereof

The invention provides novel compounds having the general formula I: wherein R, R, R, n, p, q, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.

Bicyclic sulfones and sulfoxides and methods of use thereof

The invention provides novel compounds having the general formula I: wherein R, X, Z, L, n, the A ring, the B ring, and the C ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.

Bicyclic lactams and methods of use thereof

The invention provides novel compounds having the general formula I: wherein R, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.

Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.

Therapeutic compounds, compositions and methods of use thereof

The invention provides novel compounds having the general formula I: or pharmaceutically acceptable salts thereof, whereinR, R, R, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.

Bicyclic compounds for use as RIP1 kinase inhibitors

The invention provides novel compounds having the general formula I: wherein R, R, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.

Bicyclic amide compounds and methods of use thereof

The invention provides novel compounds having RIP1 kinase inhibitory activity, pharmaceutical compositions including the compounds and methods of using the compounds.

Inhibitors of RIP1 kinase and methods of use thereof

The discovery of distinct modes of asymmetric catalysis has the potential to rapidly advance chemists' ability to build enantioenriched molecules. As an example, the use of chiral cation salts as phase-transfer catalysts for anionic reagents has enabled a vast set of enantioselective transformations. A largely overlooked analogous mechanism wherein a chiral anionic catalyst brings a cationic species into solution is itself a powerful method. The concept is broadly applicable to a number of different reaction pathways, including to the enantioselective fluorocyclization of olefins, and dearomatization of aromatic systems with a cationic electrophile-transferring (e.g., fluorinating) agent and a chiral phosphate catalyst. The reactions proceed in high yield and stereoselectivity. The compounds and methods of the invention are of particular value, especially considering the scarcity of alternative approaches.

Growing community of inventors

San Mateo, CA, United States of America

Gregory Hamilton